Nothing said here yet.
to join the conversation.
| LEFKOFSKY ERIC PCEO and Chairman | Sell | 38,489 | $2.8M | Tue, Oct 27 |
| LEFKOFSKY ERIC PCEO and Chairman | Sell | 35,759 | $2.6M | Tue, Oct 27 |
| LEFKOFSKY ERIC PCEO and Chairman | Sell | 24,597 | $1.7M | Tue, Oct 27 |
| LEFKOFSKY ERIC PCEO and Chairman | Sell | 17,825 | $1.2M | Tue, Oct 27 |
| LEFKOFSKY ERIC PCEO and Chairman | Sell | 16,414 | $1.2M | Tue, Oct 27 |
| LEFKOFSKY ERIC PCEO and Chairman | Sell | 15,259 | $1.1M | Tue, Oct 27 |
| LEFKOFSKY ERIC PCEO and Chairman | Sell | 14,820 | $1.0M | Tue, Oct 27 |
| LEFKOFSKY ERIC PCEO and Chairman | Sell | 14,237 | $1.0M | Tue, Oct 27 |
| LEFKOFSKY ERIC PCEO and Chairman | Sell | 13,209 | $955.1K | Tue, Oct 27 |
| LEFKOFSKY ERIC PCEO and Chairman | Sell | 10,428 | $702.4K | Tue, Oct 27 |
| LEFKOFSKY ERIC PCEO and Chairman | Sell | 9,132 | $615.1K | Tue, Oct 27 |
| LEFKOFSKY ERIC PCEO and Chairman | Sell | 7,592 | $516.3K | Tue, Oct 27 |
Ark Invest increased its exposure to several widely followed biotechnology stocks during the session.
Tempus AI or Doximity: Which medical information systems stock offers better value? Compare growth prospects, AI expansion, earnings estimates and valuation.
For questions about this article or underlying research, email [email protected].
Tempus AI (TEM) just deepened its ties with Bristol Myers Squibb and Pathos AI, securing long-term data licensing deals that spotlight its role in real-world oncology and neuroscience datasets.
Tempus AI heads into its Nov. 2 earnings report with a $1.5 billion acquisition pending and shares down more than 20% in a month, putting serious pressure on the core business to prove it can carry the weight.
Tempus (TEM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
For questions about this article or underlying research, email [email protected].
Key TakeawaysTempus AI shares rose 6% today after Bristol Myers Squibb agreed to license Tempus’s oncology data through 2031 and use its Lens AI platform.